Peptides and Cortisol: How Peptides Affect Stress Hormones

Cortisol -- the primary glucocorticoid stress hormone -- sits at the intersection of nearly every system that peptide users care about: body composition, sleep quality, immune function, recovery, and cognitive performance. Understanding how different peptides interact with cortisol and the broader hypothalamic-pituitary-adrenal (HPA) axis is essential for designing protocols that work with your physiology rather than against it.

The relationship is more complex than most peptide guides acknowledge. Some peptides directly modulate HPA axis activity. Others affect cortisol indirectly through downstream hormonal cascades. And the clinical significance of peptide-induced cortisol changes depends heavily on individual baseline cortisol status, timing, and the magnitude of the shift.

The HPA axis: a brief primer

The hypothalamic-pituitary-adrenal axis is the body's central stress response system:

1. Hypothalamus releases corticotropin-releasing hormone (CRH) in response to physical or psychological stress
2. Anterior pituitary responds to CRH by releasing adrenocorticotropic hormone (ACTH)
3. Adrenal cortex responds to ACTH by producing cortisol
4. Cortisol feeds back to the hypothalamus and pituitary to suppress further CRH and ACTH release (negative feedback)

This negative feedback loop maintains cortisol within a physiological range. Chronic stress, sleep deprivation, overtraining, and certain medical conditions can dysregulate this loop -- leading to either chronically elevated cortisol (Cushing-like presentations) or blunted cortisol response (HPA axis suppression, sometimes called "adrenal fatigue" in functional medicine, though this term is not recognized in conventional endocrinology).

Peptides can interact with this axis at multiple points: CRH release, ACTH sensitivity, adrenal cortisol production, and negative feedback sensitivity.

Peptides that lower cortisol

Selank

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics (Russian Academy of Sciences) as an analog of tuftsin, an endogenous immunomodulatory tetrapeptide. It is approved in Russia as an anxiolytic medication.

Evidence for cortisol effects:

• In a clinical study of patients with generalized anxiety disorder, Selank (at anxiolytic doses) normalized elevated cortisol levels, bringing them toward the physiological range without suppressing cortisol below normal
• Animal studies demonstrate that Selank modulates the GABAergic system -- increasing GABA-A receptor sensitivity and enhancing inhibitory neurotransmission. GABA activity suppresses CRH release from the hypothalamus, reducing downstream ACTH and cortisol
• Selank increased BDNF (brain-derived neurotrophic factor) expression in animal models, which independently supports HPA axis regulation
• The anxiolytic effect appears to be mediated through enkephalin degradation inhibition, increasing endogenous opioid peptide activity

Clinical significance: Selank does not suppress cortisol indiscriminately. Preclinical data suggests it acts as a modulator -- normalizing elevated cortisol associated with anxiety states rather than driving cortisol below physiological levels. This distinction matters: indiscriminate cortisol suppression would impair immune function, glucose regulation, and stress resilience.

Typical protocol: 200-400 mcg intranasally, 1-3 times daily. The intranasal route provides rapid CNS access. Effects on subjective anxiety are often reported within 15-30 minutes.

NA-Selank-Amidate

NA-Selank-Amidate (N-Acetyl Selank Amidate) is a modified version of Selank with N-terminal acetylation and C-terminal amidation. These modifications increase enzymatic stability and potentially enhance CNS bioavailability.

The cortisol-modulating mechanisms are presumed to be similar to Selank, though direct comparative studies between the two forms are limited. The enhanced stability may provide a more sustained effect, which could be advantageous for individuals with persistent HPA axis dysregulation.

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a nine-amino-acid neuropeptide first isolated from rabbit brain in 1977. Its name derives from its original characterization as a sleep-promoting substance, though subsequent research suggests a broader neuromodulatory role.

Evidence for cortisol effects:

• Early clinical studies (Schneider-Helmert, 1987) reported that DSIP normalized abnormal cortisol rhythms in patients with insomnia -- reducing elevated nighttime cortisol while preserving the normal morning cortisol peak
• DSIP appears to modulate the circadian cortisol rhythm rather than simply suppressing total cortisol output. This is a critical distinction: cortisol should be high in the morning (supporting wakefulness and glucose mobilization) and low at night (permitting sleep onset and recovery)
• Animal studies suggest DSIP modulates CRH release at the hypothalamic level, potentially by interacting with GABA and serotonin systems
• Some evidence suggests DSIP enhances cortisol negative feedback sensitivity -- meaning the HPA axis becomes more responsive to cortisol's own suppressive signal

Clinical significance: DSIP's cortisol effects are most relevant for individuals with disrupted circadian cortisol patterns -- specifically, elevated evening cortisol that interferes with sleep onset. Preclinical data suggests the effect is restorative (normalizing rhythmicity) rather than suppressive.

Typical protocol: 100-300 mcg SC or IM, 30-60 minutes before bedtime. Cycles of 10-30 days are commonly reported.

Semax

Semax is a synthetic heptapeptide analog of ACTH(4-10) -- the active fragment of adrenocorticotropic hormone. Paradoxically, despite being derived from ACTH, Semax does not stimulate cortisol production. The fragment retains ACTH's neurotrophic properties (BDNF upregulation, cognitive enhancement) while lacking the adrenal-stimulating activity of full-length ACTH.

Evidence for cortisol effects:

• Semax has been shown in animal studies to increase BDNF and NGF (nerve growth factor) expression, both of which support HPA axis regulation
• Clinical use in Russia (approved as a nootropic and neuroprotective agent) has not reported cortisol elevation as a side effect
• One animal study suggested mild cortisol-lowering effects through enhanced negative feedback sensitivity, but this is not robustly replicated

Clinical significance: Semax is best characterized as cortisol-neutral rather than cortisol-lowering. Its inclusion here is primarily to clarify a common misconception -- its structural relationship to ACTH does not translate into ACTH-like cortisol stimulation.

Peptides that may elevate cortisol

Growth hormone secretagogues

Growth hormone secretagogues -- including ipamorelin, sermorelin, GHRP-2, GHRP-6, and hexarelin -- stimulate pituitary GH release through different mechanisms. Their interaction with cortisol is often overlooked.

The GH-cortisol connection:

Peptide	GH release mechanism	Cortisol effect	Magnitude
Ipamorelin	Selective GH via ghrelin receptor	Minimal cortisol increase	Very low
Sermorelin	GH via GHRH receptor	No significant cortisol effect	Negligible
GHRP-2	GH via ghrelin receptor + ACTH stimulation	Moderate cortisol increase	Clinically relevant
GHRP-6	GH via ghrelin receptor + ACTH stimulation	Moderate cortisol increase	Clinically relevant
Hexarelin	GH via ghrelin receptor + ACTH stimulation	Significant cortisol increase	Clinically relevant
Ibutamoren (MK-677)	Oral GH secretagogue via ghrelin receptor	Mild cortisol increase (acute)	Low-moderate

Key distinctions:

Ipamorelin is considered the most selective GH secretagogue precisely because it does not significantly stimulate ACTH or cortisol release. In clinical studies (Raun et al., 1998), ipamorelin produced dose-dependent GH release without the proportional ACTH and cortisol elevation seen with GHRP-6 and hexarelin. This selectivity is one of the primary reasons ipamorelin is preferred in peptide protocols where cortisol management is a concern.

GHRP-2 and GHRP-6 are less selective. They stimulate ACTH release from the pituitary in addition to GH, resulting in measurable cortisol elevation. In clinical testing, GHRP-2 at standard doses produced cortisol increases of approximately 25-50% above baseline. This effect is typically transient (returning to baseline within 2-3 hours) but may accumulate with chronic twice-daily dosing.

Hexarelin produces the most pronounced cortisol elevation among GH secretagogues. It also has the issue of tachyphylaxis (reduced GH response with repeated use), making it less commonly used in sustained protocols.

Sermorelin acts through the GHRH receptor (distinct from the ghrelin receptor used by GHRPs) and does not stimulate ACTH. It is considered cortisol-neutral in clinical pharmacology.

Practical implications for GH secretagogue selection

For individuals with already-elevated cortisol (high-stress lifestyles, overtraining, poor sleep):

• Prefer: ipamorelin or sermorelin -- minimal cortisol impact
• Use cautiously: GHRP-2, GHRP-6 -- transient cortisol elevation may compound existing excess
• Avoid: hexarelin -- most pronounced ACTH/cortisol stimulation

For individuals with low or normal cortisol:

• The cortisol-stimulating effect of GHRP-2/GHRP-6 is less concerning and may even be marginally beneficial for morning cortisol support

Cortisol testing: what to measure and when

Understanding your cortisol status is important for selecting and monitoring peptide protocols. The testing landscape:

Serum cortisol (blood draw)

• Best for: single-point cortisol assessment
• Timing matters: morning cortisol (7-9 AM) should be 10-20 mcg/dL; afternoon cortisol drops to roughly half morning values
• Limitation: captures only one moment; does not reveal circadian pattern or cumulative daily output

Salivary cortisol (4-point diurnal curve)

• Best for: assessing circadian cortisol rhythm
• Protocol: four saliva samples across the day (morning, noon, afternoon, bedtime)
• Advantage: reveals whether the cortisol curve is normal (high morning, declining through the day) or disrupted (flat curve, elevated evening cortisol, or blunted morning response)
• Most relevant for peptide users: identifies whether evening cortisol is elevated (suggesting DSIP or Selank may be appropriate) or morning cortisol is blunted (suggesting cortisol-neutral protocols are preferred)

DUTCH test (dried urine cortisol metabolites)

• Best for: comprehensive HPA axis assessment
• Measures: cortisol, cortisone, and their metabolites across the full day
• Advantage: reveals cortisol production, clearance, and the cortisol-to-cortisone ratio (11-beta-HSD enzyme activity)
• Limitation: cost; not available through standard medical labs

When to test

• Baseline: before initiating any peptide protocol affecting the HPA axis
• 4-6 weeks: after starting a cortisol-modulating peptide (Selank, DSIP) or a GH secretagogue
• Symptoms: if new symptoms suggestive of cortisol dysregulation appear (insomnia, anxiety, afternoon fatigue, morning sluggishness, unexplained weight gain around the midsection)

Cortisol, recovery, and body composition

Cortisol's effects on peptide goals are dose- and timing-dependent:

Normal cortisol patterns support:

• Morning alertness and metabolic activation
• Appropriate immune response and inflammation resolution
• Exercise performance (acute cortisol rise during training is normal and beneficial)
• Fat mobilization during fasting

Chronically elevated cortisol impairs:

• Muscle protein synthesis (cortisol is catabolic at sustained high levels)
• Sleep quality (elevated evening cortisol inhibits melatonin secretion)
• Immune function (sustained cortisol suppresses immune surveillance)
• Fat loss (chronic cortisol promotes visceral fat deposition through 11-beta-HSD activity in adipose tissue)
• GH secretion (cortisol suppresses pulsatile GH release, partially negating the effect of GH secretagogues)

Chronically suppressed cortisol impairs:

• Stress tolerance and exercise capacity
• Anti-inflammatory regulation (paradoxically, very low cortisol can worsen inflammation)
• Morning wakefulness and circadian alignment

The practical takeaway: peptide protocols should aim to normalize cortisol rhythm, not simply suppress cortisol. Indiscriminate cortisol reduction with anxiolytic peptides is as problematic as ignoring cortisol elevation.

Building a cortisol-aware peptide protocol

Scenario 1: high-stress individual with elevated cortisol

Goals: reduce excess cortisol, improve sleep, support recovery

Time	Peptide	Rationale
Morning	Semax (200-600 mcg intranasal)	Cognitive support without cortisol elevation
Evening	Selank (200-400 mcg intranasal)	Anxiolytic, cortisol-normalizing
Bedtime	DSIP (100-200 mcg SC)	Normalize nighttime cortisol, support sleep
If using GH secretagogue	Ipamorelin or sermorelin	Minimal cortisol impact

Scenario 2: recovery-focused athlete with normal cortisol

Goals: optimize GH secretion for recovery without disrupting cortisol

Time	Peptide	Rationale
Pre-bed	Ipamorelin (100-300 mcg SC)	GH pulse without cortisol elevation
Optional AM	Sermorelin (100-300 mcg SC)	GHRH-pathway GH support, cortisol-neutral
If anxious	Selank (200 mcg intranasal, as needed)	Acute anxiolytic without cortisol suppression

Scenario 3: poor morning cortisol (blunted AM response)

Goals: support morning cortisol without chronic elevation

• Avoid: DSIP (may further suppress already-low cortisol)
• Consider: GHRP-2 at low dose in the morning (mild cortisol-stimulating effect may support morning activation)
• Support: circadian hygiene measures are more important than peptides for this pattern -- morning bright light exposure, consistent wake time, and physical activity in the first 2 hours after waking

Common mistakes in cortisol management with peptides

Stacking multiple cortisol-suppressing peptides without monitoring. Combining Selank, DSIP, and other anxiolytic peptides without baseline and follow-up cortisol testing risks driving cortisol below the functional range, impairing stress tolerance and immune function.

Using GHRP-6 or hexarelin at high doses without considering cortisol. Individuals already under chronic stress may experience compounded cortisol elevation with less-selective GH secretagogues, partially negating the recovery benefits they sought from GH optimization.

Ignoring timing. Cortisol is inherently circadian. Selank at bedtime makes sense (lowering evening cortisol for sleep); Selank upon morning waking may blunt the cortisol awakening response that supports daytime alertness.

Confusing correlation with causation in subjective reports. Feeling calmer on Selank does not necessarily mean cortisol decreased. Feeling wired on GHRP-2 does not necessarily mean cortisol is problematically elevated. Objective testing is necessary to confirm HPA axis changes.

FAQ

Does Selank lower cortisol permanently?

No. Preclinical data suggests Selank modulates cortisol acutely while in use, normalizing elevated levels toward the physiological range. It does not permanently reset HPA axis setpoints. When Selank is discontinued, cortisol patterns will return toward baseline levels. If the underlying stressors driving cortisol elevation are not addressed, elevated cortisol will likely return.

Can peptides cause adrenal fatigue?

"Adrenal fatigue" is not a recognized diagnosis in conventional endocrinology -- the adrenal glands do not "fatigue" in the way this term implies. However, chronic HPA axis suppression is a real clinical phenomenon (most commonly seen with exogenous corticosteroid use). There is no evidence that anxiolytic peptides like Selank or DSIP cause clinically significant HPA axis suppression at standard doses and cycle lengths. Nonetheless, monitoring cortisol during extended use is prudent.

Should I take Selank in the morning or at night?

This depends on your cortisol pattern. If you have elevated evening cortisol interfering with sleep, evening use is logical. If you experience anxiety throughout the day, divided doses (morning and evening) are reported by some practitioners. However, using Selank exclusively in the early morning could potentially blunt the cortisol awakening response, which supports daytime alertness. A 4-point salivary cortisol test can help determine optimal timing.

Do GH peptides increase cortisol enough to affect body composition?

For ipamorelin and sermorelin, the cortisol effect is minimal and unlikely to affect body composition. For GHRP-2, GHRP-6, and hexarelin, the cortisol elevation is transient (2-3 hours) and probably insufficient to drive meaningful body composition changes on its own. However, if someone is already chronically cortisol-elevated and adds a non-selective GH secretagogue, the cumulative cortisol burden could contribute to impaired fat loss and muscle protein synthesis.

How often should I test cortisol while using peptides?

A reasonable minimum is baseline testing before starting any cortisol-modulating peptide, followed by a retest at 4-6 weeks. A 4-point salivary cortisol test provides the most useful information for peptide protocol optimization because it reveals the circadian pattern, not just a single-point snapshot. If your protocol includes multiple peptides affecting the HPA axis, more frequent monitoring (every 4 weeks) during the initial adjustment period is prudent.

Can I use cortisol-lowering peptides with cortisol-elevating ones?

Yes, and this is actually a common scenario. For example, using ipamorelin (mild cortisol-neutral GH secretagogue) alongside Selank (anxiolytic cortisol modulator) is a widely reported combination. The theoretical concern arises when combining strongly cortisol-elevating peptides (hexarelin, high-dose GHRP-2) with strongly cortisol-suppressing peptides (high-dose DSIP plus Selank). In these cases, the net effect on cortisol is unpredictable without testing, and monitoring becomes more important.